2021
Tandem high-dose influenza vaccination is associated with more durable serologic immunity in patients with plasma cell dyscrasias
Branagan AR, Duffy E, Gan G, Li F, Foster C, Verma R, Zhang L, Parker TL, Seropian S, Cooper DL, Brandt D, Kortmansky J, Witt D, Ferencz TM, Dhodapkar KM, Dhodapkar MV. Tandem high-dose influenza vaccination is associated with more durable serologic immunity in patients with plasma cell dyscrasias. Blood Advances 2021, 5: 1535-1539. PMID: 33683337, PMCID: PMC7948269, DOI: 10.1182/bloodadvances.2020003880.Peer-Reviewed Original ResearchConceptsHigh-dose influenza vaccinationPlasma cell dyscrasiaInfluenza vaccinationProtective immunityCell dyscrasiaPCD patientsPlacebo-controlled clinical trialHigh-dose vaccinationHigh-dose vaccineInfluenza-specific immunityBurden of influenzaSaline placebo injectionsAge-based vaccinationHigher seroprotectionSerologic immunityPlacebo injectionsVaccine strategiesTiter responseClinical trialsFlu seasonPatientsVaccinationImmunityNovel coronavirusSeroprotectionMitigating the risk of COVID-19 exposure by transitioning from clinic-based to home-based immune globulin infusion
Perreault S, Schiffer M, Clinchy-Jarmoszko V, Bocchetta N, Barbarotta L, Abdelghany O, Foss F, Huntington S, Seropian S, Isufi I. Mitigating the risk of COVID-19 exposure by transitioning from clinic-based to home-based immune globulin infusion. American Journal Of Health-System Pharmacy 2021, 78: 1112-1117. PMID: 33617630, PMCID: PMC7929449, DOI: 10.1093/ajhp/zxab072.Peer-Reviewed Original ResearchConceptsHome-based infusionsCOVID-19 exposureSCIG infusionsIntravenous immune globulin therapyBetter patient understandingImmune globulin infusionImmune globulin therapyPatient Outcome QuestionnairePatient outcome assessmentInfusion-related complicationsChair timeRisk of infectionCoronavirus disease 2019 (COVID-19) virusGlobulin therapyIVIG infusionIVIG therapyChart reviewImmunosuppressed populationImmunosuppressed patientsInfusion visitsMedical visitsOutcomes QuestionnairePatient satisfactionPatient understandingInfusion clinicClinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study
Sharma A, Bhatt NS, St Martin A, Abid MB, Bloomquist J, Chemaly RF, Dandoy C, Gauthier J, Gowda L, Perales MA, Seropian S, Shaw BE, Tuschl EE, Zeidan AM, Riches ML, Shah GL. Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study. The Lancet Haematology 2021, 8: e185-e193. PMID: 33482113, PMCID: PMC7816949, DOI: 10.1016/s2352-3026(20)30429-4.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsAllogeneic HSCT recipientsAutologous HSCT recipientsHaematopoietic stem cell transplantation recipientsStem cell transplantation recipientsCOVID-19 diagnosisHSCT recipientsNational Cancer InstituteHigh riskAllogeneic HSCTOverall survivalTransplantation recipientsCOVID-19Cancer InstituteCox proportional hazards modelAggressive treatment measuresSurvival 30 daysObservational cohort studyMarrow Transplant ResearchPoor overall survivalAge 50 yearsOverall survival probabilityPlasma cell disordersMonths of transplantationProportional hazards modelNational InstituteChallenges in the Evaluation and Management of Toxicities Arising From Immune Checkpoint Inhibitor Therapy for Patients With Myeloid Malignancies
Shallis RM, Bewersdorf JP, Swoboda DM, Wei W, Gowda L, Prebet T, Halene S, Pillai MM, Parker T, Neparidze N, Podoltsev NA, Seropian S, Sallman DA, Gore SD, Zeidan AM. Challenges in the Evaluation and Management of Toxicities Arising From Immune Checkpoint Inhibitor Therapy for Patients With Myeloid Malignancies. Clinical Lymphoma Myeloma & Leukemia 2021, 21: e483-e487. PMID: 33551344, DOI: 10.1016/j.clml.2021.01.003.Peer-Reviewed Original Research
2020
Attenuated Novel SARS Coronavirus 2 Infection in an Allogeneic Hematopoietic Stem Cell Transplant Patient on Ruxolitinib
Foss FM, Rubinowitz A, Landry ML, Isufi I, Gowda L, Seropian S, Perreault S, Shenoi SV. Attenuated Novel SARS Coronavirus 2 Infection in an Allogeneic Hematopoietic Stem Cell Transplant Patient on Ruxolitinib. Clinical Lymphoma Myeloma & Leukemia 2020, 20: 720-723. PMID: 32727701, PMCID: PMC7316063, DOI: 10.1016/j.clml.2020.06.014.Peer-Reviewed Original ResearchMeSH KeywordsBetacoronavirusCoronavirus InfectionsCOVID-19COVID-19 Drug TreatmentGraft vs Host DiseaseHematopoietic Stem Cell TransplantationHumansImmunocompromised HostLymphoma, T-CellMaleMiddle AgedNitrilesPandemicsPneumonia, ViralPyrazolesPyrimidinesSARS-CoV-2Severity of Illness IndexTransplantation, HomologousTreatment OutcomeConceptsAllogeneic hematopoietic stem cell transplant patientsHematopoietic stem cell transplant patientsSevere acute respiratory syndrome coronavirus 2SARS coronavirus 2 (SARS-CoV-2) infectionSARS-CoV-2 pneumoniaAcute respiratory syndrome coronavirus 2Stem cell transplant patientsSARS-CoV-2 infectionRespiratory syndrome coronavirus 2Coronavirus 2 infectionCell transplant patientsCoV-2 infectionStem cell transplantationSyndrome coronavirus 2High death rateImmunocompromised stateJAK/STAT inhibitor ruxolitinibTransplant patientsCell transplantationCoronavirus 2Novel therapiesInhibitor ruxolitinibPatientsDeath rateRuxolitinibTocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019 Survival and Clinical Outcomes
Price CC, Altice FL, Shyr Y, Koff A, Pischel L, Goshua G, Azar MM, Mcmanus D, Chen SC, Gleeson SE, Britto CJ, Azmy V, Kaman K, Gaston DC, Davis M, Burrello T, Harris Z, Villanueva MS, Aoun-Barakat L, Kang I, Seropian S, Chupp G, Bucala R, Kaminski N, Lee AI, LoRusso PM, Topal JE, Dela Cruz C, Malinis M. Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019 Survival and Clinical Outcomes. CHEST Journal 2020, 158: 1397-1408. PMID: 32553536, PMCID: PMC7831876, DOI: 10.1016/j.chest.2020.06.006.Peer-Reviewed Original ResearchConceptsCytokine release syndromeTocilizumab-treated patientsSevere diseaseRelease syndromeTocilizumab treatmentInflammatory biomarkersNonsevere diseaseSoluble IL-2 receptor levelsHigh-sensitivity C-reactive proteinIL-2 receptor levelsConsecutive COVID-19 patientsIL-6 receptor antagonistMechanical ventilation outcomesC-reactive proteinCOVID-19 patientsHigher admission levelsRace/ethnicityMV daysVentilation outcomesAdverse eventsChart reviewClinical responseMedian ageWhite patientsClinical outcomesCardiotoxicity in Hematopoietic Stem Cell Transplant: Keeping the Beat
Baker JK, Shank-Coviello J, Zhou B, Dixon J, McCorkle R, Sarpong D, Medoff E, Cooper D, Seropian S, Dai F. Cardiotoxicity in Hematopoietic Stem Cell Transplant: Keeping the Beat. Clinical Lymphoma Myeloma & Leukemia 2020, 20: 244-251.e4. PMID: 32067953, DOI: 10.1016/j.clml.2019.12.027.Peer-Reviewed Original ResearchConceptsHematopoietic stem cell transplantCardiac eventsStem cell transplantCell transplantAtrial arrhythmiasAcute heart failureInstances of bradycardiaNew-onset hypertensionAcute coronary syndromeCoronary artery diseaseRisk of deathMultivariable regression analysisCoronary syndromeOnset hypertensionHSCT populationArtery diseaseHeart failureHSCT outcomesPericardial effusionAtrial dilationVentricular arrhythmiasSingle institutionSubgroup analysisBody of evidenceMedical history
2019
Allogeneic stem cell transplantation and combination antiretroviral therapy: cautions, complications, and considerations
Shallis RM, Gleeson S, Azar M, Malinis M, Xu ML, Seropian SE, Gowda L, Zeidan AM. Allogeneic stem cell transplantation and combination antiretroviral therapy: cautions, complications, and considerations. Leukemia & Lymphoma 2019, 60: 2584-2587. PMID: 30943051, DOI: 10.1080/10428194.2019.1594221.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsThe impact of a multimodal approach to vancomycin discontinuation in hematopoietic stem cell transplant recipients (HSCT) with febrile neutropenia (FN)
Perreault S, McManus D, Bar N, Foss F, Gowda L, Isufi I, Seropian S, Malinis M, Topal JE. The impact of a multimodal approach to vancomycin discontinuation in hematopoietic stem cell transplant recipients (HSCT) with febrile neutropenia (FN). Transplant Infectious Disease 2019, 21: e13059. PMID: 30737868, DOI: 10.1111/tid.13059.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAnti-Bacterial AgentsAntimicrobial StewardshipFebrile NeutropeniaFemaleHematopoietic Stem Cell TransplantationHumansMaleMedication Therapy ManagementMethicillin-Resistant Staphylococcus aureusMiddle AgedNoseRetrospective StudiesStaphylococcal InfectionsTime FactorsVancomycinYoung AdultConceptsHematopoietic stem cell transplant recipientsPost-intervention cohortFebrile neutropeniaVancomycin useVancomycin discontinuationStewardship teamRetrospective analysisMultimodal approachStem cell transplant recipientsResistant Gram-positive organismsResistant Gram-positive infectionsAntibiotic stewardship teamDiscontinuation of vancomycinEvidence of pneumoniaPost-implementation cohortPrevious MRSA infectionCell transplant recipientsGram-positive infectionsNasal swab collectionEmpiric vancomycinFN patientsVancomycin ordersVancomycin usageHSCT recipientsTransplant recipients
2018
Long-term follow-up of a single institution pilot study of sirolimus, tacrolimus, and short course methotrexate for graft versus host disease prophylaxis in mismatched unrelated donor allogeneic stem cell transplantation
Kim TK, DeVeaux M, Stahl M, Perreault S, Isufi I, Cooper D, Foss F, Shlomchik W, Zelterman D, Zeidan AM, Seropian S. Long-term follow-up of a single institution pilot study of sirolimus, tacrolimus, and short course methotrexate for graft versus host disease prophylaxis in mismatched unrelated donor allogeneic stem cell transplantation. Annals Of Hematology 2018, 98: 237-240. PMID: 30027436, DOI: 10.1007/s00277-018-3427-1.Peer-Reviewed Original ResearchConceptsUnrelated donor allogeneic stem cell transplantationDonor allogeneic stem cell transplantationAllogeneic stem cell transplantationSingle-institution pilot studyHost disease (GVHD) prophylaxisShort-course methotrexateStem cell transplantationDisease prophylaxisCell transplantationPilot studyProphylaxisTacrolimusSirolimusTransplantationMethotrexateGraft
2017
Transplantation in the Treatment of Primary Cutaneous Aggressive Epidermotropic Cytotoxic CD8-Positive T-Cell Lymphoma
Cyrenne BM, Gibson JF, Subtil A, Girardi M, Isufi I, Seropian S, Foss F. Transplantation in the Treatment of Primary Cutaneous Aggressive Epidermotropic Cytotoxic CD8-Positive T-Cell Lymphoma. Clinical Lymphoma Myeloma & Leukemia 2017, 18: e85-e93. PMID: 29223388, DOI: 10.1016/j.clml.2017.11.004.Peer-Reviewed Original ResearchConceptsHematopoietic stem cell transplantationT-cell lymphomaAllogeneic hematopoietic stem cell transplantationNovel agentsPeripheral T-cell lymphomaPositive T-cell lymphomaDiagnosis of CD8Retrospective case seriesStandardized treatment strategyStem cell transplantationPotential curative therapyCourse of treatmentPromising treatment modalityHistone deacetylase inhibitorsSustained remissionCombination chemotherapyCurative therapyCase seriesPoor outcomeRare subtypeTreatment courseAvailable therapiesCell transplantationTreatment modalitiesTreatment strategiesClinical and Serologic Responses After a Two-dose Series of High-dose Influenza Vaccine in Plasma Cell Disorders: A Prospective, Single-arm Trial
Branagan AR, Duffy E, Albrecht RA, Cooper DL, Seropian S, Parker TL, Gan G, Li F, Zelterman D, Boddupalli CS, Zhang L, Verma R, Ferencz TM, Dhodapkar MV. Clinical and Serologic Responses After a Two-dose Series of High-dose Influenza Vaccine in Plasma Cell Disorders: A Prospective, Single-arm Trial. Clinical Lymphoma Myeloma & Leukemia 2017, 17: 296-304.e2. PMID: 28343904, PMCID: PMC5413398, DOI: 10.1016/j.clml.2017.02.025.Peer-Reviewed Original ResearchConceptsPlasma cell disordersSerologic responseInfluenza vaccinationInfluenza vaccineMultiple myelomaCell disordersInfluenza infectionVaccination strategiesHigh-dose influenza vaccineInactivated trivalent influenza vaccineLaboratory-confirmed influenza infectionBooster vaccination strategiesStandard vaccination strategyTwo-dose seriesLaboratory-confirmed influenzaSeasonal influenza vaccinationTrivalent influenza vaccineSingle-arm trialPlasma cell dyscrasiaDisease response assessmentLogistic regression modelsSeroprotection ratesActive therapyAdverse eventsPartial response
2016
Serial Native T1 Mapping to Monitor Cardiac Response to Treatment in Light-Chain Amyloidosis
Hur DJ, Dicks DL, Huber S, Mojibian HR, Meadows JL, Seropian SE, Baldassarre LA. Serial Native T1 Mapping to Monitor Cardiac Response to Treatment in Light-Chain Amyloidosis. Circulation Cardiovascular Imaging 2016, 9: e004770. PMID: 27682238, DOI: 10.1161/circimaging.116.004770.Peer-Reviewed Original ResearchInfusion reactions are common after high-dose carmustine in BEAM chemotherapy and are not reduced by lengthening the time of administration
Perreault S, Baker J, Medoff E, Pratt K, Foss F, Isufi I, Seropian S, Cooper DL. Infusion reactions are common after high-dose carmustine in BEAM chemotherapy and are not reduced by lengthening the time of administration. Supportive Care In Cancer 2016, 25: 205-208. PMID: 27614867, DOI: 10.1007/s00520-016-3399-4.Peer-Reviewed Original ResearchAdolescentAdultAgedAntineoplastic Combined Chemotherapy ProtocolsCarmustineCytarabineDose-Response Relationship, DrugDrug Administration ScheduleEtoposideFemaleHematopoietic Stem Cell TransplantationHumansInfusions, IntravenousMaleMelphalanMiddle AgedTransplantation ConditioningTransplantation, AutologousYoung AdultAutologous Stem Cell Mobilization in the Age of Plerixafor
Cooper DL, Medoff E, Patel N, Baker J, Pratt K, Foss F, Seropian SE, Perreault S, Wu Y. Autologous Stem Cell Mobilization in the Age of Plerixafor. Clinical Lymphoma Myeloma & Leukemia 2016, 16: 411-416. PMID: 27245311, DOI: 10.1016/j.clml.2016.04.007.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntigens, CD34BenzylaminesCyclamsFemaleGraft SurvivalGranulocyte Colony-Stimulating FactorHematopoietic Stem Cell MobilizationHematopoietic Stem Cell TransplantationHematopoietic Stem CellsHeterocyclic CompoundsHumansLymphomaMaleMiddle AgedMultiple MyelomaTreatment OutcomeWorkflowConceptsStem cell mobilizationCell mobilizationPlerixafor useG-CSFAutologous stem cell transplantationAutologous stem cell mobilizationGranulocyte-colony stimulating factor (G-CSF) mobilizationDose of plerixaforLess platelet transfusionsStem cell transplantationCD34 cells/Treatment of myelomaCells/High-risk factorsEnough stem cellsStem cellsHematologic tolerancePosttransplantation therapyRelapsed lymphomaPlatelet transfusionsCell transplantationRisk factorsFactor mobilizationPatientsPlerixaforExpression of CD30 as a biomarker to predict response to brentuximab vedotin
Xu ML, Acevedo-Gadea C, Seropian S, Katz SG. Expression of CD30 as a biomarker to predict response to brentuximab vedotin. Histopathology 2016, 69: 155-158. PMID: 26648051, PMCID: PMC7064871, DOI: 10.1111/his.12914.Peer-Reviewed Original Research
2015
The use of basiliximab–infliximab combination for the treatment of severe gastrointestinal acute GvHD
Nadeau M, Perreault S, Seropian S, Foss F, Isufi I, Cooper DL. The use of basiliximab–infliximab combination for the treatment of severe gastrointestinal acute GvHD. Bone Marrow Transplantation 2015, 51: 273-276. PMID: 26479982, DOI: 10.1038/bmt.2015.247.Peer-Reviewed Original ResearchConceptsGastrointestinal acute GVHDAcute GVHDGrade IIIAllogeneic stem cell transplantCombination of basiliximabSevere GI GvHDSevere grade IIISteroid-refractory diseaseLong-term survivorsStem cell transplantOverall response rateCurrent retrospective studyChronic GVHDGI GVHDSalvage therapySteroid therapyPrimary diseaseCell transplantMedian timeSignificant morbidityPoor outcomeRetrospective studyGVHDMost deathsNew agentsOutcomes of acute leukemia patients transplanted with naive T cell–depleted stem cell grafts
Bleakley M, Heimfeld S, Loeb KR, Jones LA, Chaney C, Seropian S, Gooley TA, Sommermeyer F, Riddell SR, Shlomchik WD. Outcomes of acute leukemia patients transplanted with naive T cell–depleted stem cell grafts. Journal Of Clinical Investigation 2015, 125: 2677-2689. PMID: 26053664, PMCID: PMC4563691, DOI: 10.1172/jci81229.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAdolescentAdrenal Cortex HormonesAdultAnimalsChronic DiseaseDisease-Free SurvivalFemaleGraft vs Host DiseaseHematopoietic Stem Cell TransplantationHistocompatibility TestingHumansKaplan-Meier EstimateLeukemiaLymphocyte DepletionMaleMiceMiddle AgedMyelodysplastic SyndromesTissue DonorsT-Lymphocyte SubsetsTransplantation ConditioningTransplantation, HomologousYoung AdultConceptsHematopoietic stem cell transplantationStem cell graftsChronic GVHDT cellsCell graftsT-cell-depleted stem cell graftsPeripheral blood stem cell graftsAllogeneic hematopoietic stem cell transplantationBlood stem cell graftsFunctional T-cell memoryT-cell-replete graftsPathogen-specific T cellsSingle-arm clinical trialT-cell recoveryVirus-specific immunityStem cell allograftsTotal body irradiationMemory T cellsStem cell transplantationT cell memoryAcute leukemia patientsHigh-risk leukemiaNaive T cellsAcute GVHDSevere GVHDClinical and pharmacodynamic analysis of pomalidomide dosing strategies in myeloma: impact of immune activation and cereblon targets
Sehgal K, Das R, Zhang L, Verma R, Deng Y, Kocoglu M, Vasquez J, Koduru S, Ren Y, Wang M, Couto S, Breider M, Hansel D, Seropian S, Cooper D, Thakurta A, Yao X, Dhodapkar KM, Dhodapkar MV. Clinical and pharmacodynamic analysis of pomalidomide dosing strategies in myeloma: impact of immune activation and cereblon targets. Blood 2015, 125: 4042-4051. PMID: 25869284, PMCID: PMC4481593, DOI: 10.1182/blood-2014-11-611426.Peer-Reviewed Original ResearchConceptsImmune activationAntitumor effectsNK cellsT cellsMore frequent adverse eventsClinical antitumor effectsFrequent adverse eventsNatural killer cellsIntermittent dosing strategyDirect antitumor effectsExpression of cytokinesT cell activationGreater tumor reductionPomalidomide/Coinhibitory receptorsAdverse eventsClinical responseOverall survivalKiller cellsPharmacodynamic effectsImmunomodulatory effectsMultiple myelomaTumor reductionIntermittent dosingPharmacodynamic analysis
2013
Monitoring patient distress and related problems before and after hematopoietic stem cell transplantation
Crooks M, Seropian S, Bai M, McCorkle R. Monitoring patient distress and related problems before and after hematopoietic stem cell transplantation. Palliative & Supportive Care 2013, 12: 53-61. PMID: 24169207, DOI: 10.1017/s1478951513000552.Peer-Reviewed Original ResearchMeSH KeywordsAdaptation, PsychologicalAdultAftercareAgedAnxiety DisordersCooperative BehaviorDepressive DisorderFemaleHematologic NeoplasmsHematopoietic Stem Cell TransplantationHospice and Palliative Care NursingHumansInterdisciplinary CommunicationMaleMass ScreeningMiddle AgedNurse-Patient RelationsNursing AssessmentPatient DischargePatient IsolationProblem SolvingPsychometricsReproducibility of ResultsSick RoleConceptsHematopoietic stem cell transplantationStem cell transplantationCell transplantationHigh-risk hematologic malignanciesPsychological distressNon-malignant diseasesIntense psychological distressHealth care teamOncology patientsStandard treatmentHematologic malignanciesPatient distressCare teamTransplant numbersPatientsTransplantationOverall treatmentMedical issuesDistressFamily membersTreatmentSocial strainRelapseMalignancyDisease